Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations.

Publication: AIDS Vaccine Week

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2008 NewsRX

Mymetics Corporation (OTCBB: MYMX), a vaccine development company, is pleased to announce their preliminary SHIV challenge results on non-human primates previously immunized with the Company's mucosal HIV-AIDS vaccine designed for triggering mucosal protection. The results significantly exceed the Industry standard of 60% to 70% effectiveness to be considered as a promising vaccine as well as of Mymetics' expectation which was considerable above this level. The Company will continue to do further tests to confirm these results and will present the all results at the Keystone Symposia. With the recent public announcements by...

Read the full article for free courtesy of your local library.